Skip to content
Low Dose GLP-1Providers

Provider review

VyrarX review

The dual agonist costs 84% more than the semaglutide program.

The widest proportional step between molecules we have found, and switching is a common path.

Reviewed by Lena OrtizMetabolic Health Editor

Price updated August 2026

How we’re funded. Some links here are affiliate links: start care through one and we may earn a commission, at no extra cost to you. Affiliate partners are listed first on our rankings — what we write about a provider is the same either way, and unflattering findings about one that pays us stay in. Full disclosure.

Price as published

VyrarX

From $179/mo semaglutide and $329/mo tirzepatide

Vs median
$10/mo above the $169 median
Market
$59–$1300/mo across 242 of 373
Structure
Standard plan, self-directed low dose
Dispensed
Pharmacy not publicly identified

Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.

In one paragraph

The verdict

Two programs, cleanly described, with what the fee covers stated for each: weekly injections, physician oversight and lifestyle coaching on both. The thing worth noticing is the gap between them. Eighty-four per cent more for the dual agonist is at the wide end of what this category charges, and it matters because switching molecules is a common path rather than an unusual one. People start on semaglutide, plateau or tolerate it poorly, and move across. Anyone who does that here is looking at a hundred and fifty dollars a month more than they started with, which is a decision better made before signing up than discovered afterwards. Both figures are floors introduced by from, so neither is the price at a working dose, and nothing above either is published anywhere. No milligram appears against either program.

Visit VyrarX

Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.

Who it suits, and who it does not

A good fit if

  • You are confident you will stay on semaglutide
  • You want physician oversight and lifestyle coaching included in the fee
  • You want the two programs described distinctly rather than as one toggle

Look elsewhere if

  • You expect to switch molecules — the step here is the widest we have found
  • You want a rate rather than a floor
  • You want a dose behind the number

What it actually costs

Price as published

Two programs, two floors: "Semaglutide Program — Weekly GLP-1 injections with physician oversight and lifestyle coaching — From $179/mo" and "Tirzepatide Program — Dual-action GLP-1/GIP therapy — From $329/mo" · THE STEP BETWEEN THEM IS THE WIDEST ON THIS PAGE IN PROPORTIONAL TERMS — $150 a month, or 84% more for the dual agonist, against a category norm running from a third more to a doubling · so anyone starting on semaglutide with an eye on switching should price the second molecule before starting rather than after · physician oversight and lifestyle coaching are named as included in both · both figures are floors and no rung above either is published · no milligram is published

Vs median
$10/mo above the $169 median across the 242 of 373 programs we track that publish a plain monthly rate
Market
$59–$1300/mo is the full published spread in our ranking
Structure
Standard plan, self-directed low dose

No low-dose product of its own. Starting low means asking for a smaller amount inside a standard plan, at the standard plan's price.

152 of the 373 programs we track price a small dose this way. The step between the molecules is the widest proportionally found so far — 84% more for the dual agonist, against a norm of a third more to a doubling. Switching molecules is a common path rather than a rare one, so a reader starting on semaglutide should price the second before starting rather than after. No low-dose product, both figures floors, no dose published.

Visit VyrarX

Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.

What is included

Consult
Included in the price
Dietitian
Included
Labs
Not required
Pricing
Varies by dose, plan or tier
Price last updated
August 2026

What it does well

  • States what the fee covers for both programs: injections, oversight and coaching.
  • Both molecules are priced openly without an intake.
  • The two programs are described distinctly rather than as one product with a toggle.

Pharmacy, labs and oversight

VyrarX does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.

Transparency check

2 of 4 published openly

What VyrarX publishes about itself, read from its own pages when we verified them — not estimated, and not a score.

Pharmacy named and regulatedNo pharmacy is identified anywhere we could find on its own pages.
Not published
A price you can read before intakeA monthly rate is published on its own pages — the figure in the price row above, read there and verified against it.
Published
What a higher dose costsPriced by dose, plan or tier, and the higher rungs are not published — the advertised figure does not tell you what a larger dose costs.
Not published
No FDA warning letter on fileChecked against the FDA's own warning-letter database; nothing on file for this company.
None on file

How the program works

Two programs, cleanly described, with what the fee covers stated for each: weekly injections, physician oversight and lifestyle coaching on both. The thing worth noticing is the gap between them. Eighty-four per cent more for the dual agonist is at the wide end of what this category charges, and it matters because switching molecules is a common path rather than an unusual one — people start on semaglutide, plateau or tolerate it poorly, and move. A reader who does that here is looking at a hundred and fifty dollars a month more, which is a decision worth making before starting rather than discovering afterwards. Both figures are floors introduced by from, so neither is the price at a working dose, and nothing above either is published. No milligram appears against either program.

The honest cons

The dual agonist costs 84% more, at the wide end of the category.
  • Both figures are floors with no rung above either published.
  • No milligram appears against either program.
Visit VyrarX

Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.

How it compares

VyrarX is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.

Where this sits

#343 of 373

Ordered with the companies that pay us first, and VyrarX is not one of them. A disclosed partition, not a score.

Compare all 373 providers →

Read this before you buy

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

Visit VyrarX

Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.

The closest alternative

RxSpan MD

From $194/mo

Vs median
$25/mo above the $169 median
Market
$59–$1300/mo across 242 of 373
Structure
Standard plan, self-directed low dose
Dispensed
Pharmacy not publicly identified

Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.

Read the RxSpan MD review →

Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.